Focus: Convert Pharmaceuticals is a Series A-stage specialty pharma company headquartered in Liège, Belgium, focused on hypoxia-activated prodrugs with current revenue entirely derived from marketed products in menopause and acute pain management.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Convert Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Single revenue driver representing 100% of company income with imminent patent expiration creates urgent commercial vulnerability.
Help build intelligence for Convert Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Convert Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Peak-lifecycle opioid with extended exclusivity through 2038 provides long-term revenue stability but limited growth potential given market dynamics.
1 discontinued, 0 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub